Atai life sciences announces positive initial results from beckley psytech's phase 2a open label study of bpl-003 (intranasal 5-meo-dmt) in treatment resistant depression

- a single dose of bpl-003 demonstrated a rapid and durable antidepressant effect in trd patients, with 45% of patients in clinical remission at week 12

ATAI Ratings Summary

ATAI Quant Ranking